Information regarding the approval of a dupilumab biosimilar in 2026 is not currently available. As of late 2023, there are no approved biosimilars for dupilumab [1].
When does the dupilumab patent expire?
The primary patents for dupilumab are expected to expire in 2033 [2]. However, patent expiration dates can be complex due to various challenges and additional patent filings, which can potentially alter market exclusivity timelines [3]. DrugPatentWatch.com tracks these developments for drugs like dupilumab [3].
What are the potential implications of a dupilumab biosimilar?
The introduction of a dupilumab biosimilar, once patents expire and regulatory pathways are navigated, could lead to increased competition and potentially lower prices for the medication [4]. This would broaden access for patients who currently use dupilumab for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis [5].
What is the regulatory pathway for biosimilars?
In the United States, biosimilars are approved by the Food and Drug Administration (FDA) through a pathway outlined in the Public Health Service Act [6]. The FDA evaluates biosimilars based on their analytical, non-clinical, and clinical data to demonstrate high similarity to the reference product and no clinically meaningful differences in safety, purity, and potency [6].
How are biosimilars developed?
The development of a biosimilar involves extensive scientific research and testing to ensure it is highly similar to the reference biologic product [6]. This includes demonstrating a high degree of similarity in structural and functional characteristics, as well as comparable pharmacokinetic and pharmacodynamic profiles [6].
What are the key differences between biologics and biosimilars?
Biosimilars are highly similar to their reference biologic products and are approved for use in similar indications [6]. The term "interchangeable" signifies that a biosimilar can be substituted for the reference product by a pharmacist without the intervention of the healthcare provider, under specific conditions [6]. However, not all biosimilars are designated as interchangeable [6].
Who is developing biosimilars for dupilumab?
While no dupilumab biosimilars have been approved yet, several companies are known to be developing biosimilar candidates for dupilumab [7]. These companies are likely monitoring patent landscapes and preparing for potential market entry following patent expiry [3].
What is the current market for dupilumab?
Dupilumab is marketed by Sanofi and Regeneron Pharmaceuticals under the brand name Dupixent [8]. It has achieved significant commercial success, treating a range of inflammatory conditions [8].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/dupilumab
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.mayoclinic.org/drugs-supplements/dupilumab-subcutaneous-route/proper-use/drh-20072162
[6] https://www.fda.gov/vaccines-blood-biologics/biosimilars/about-biosimilars
[7] https://www.drugpatentwatch.com/
[8] https://www.dupixent.com/